In focus · trending topic

beta amyloid oligomers

2 stories · following the connections

Cognition Therapeutics to Present Results of CT1812 Phase 1b/2a Clinical Study as Late Breakers at CTAD Meeting on November 2nd and 4th

By Nasdaq OMXOct 30, 2017, 12:12 PM UTC

Cognition Therapeutics CEO Kenneth I. Moch to Present at Ladenburg Thalmann 2017 Healthcare Conference

By Nasdaq OMXSep 20, 2017, 12:00 PM UTC